Alexion Pharmaceuticals (NASDAQ:ALXN) issued its quarterly earnings results on Thursday. The biopharmaceutical company reported $3.11 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.32 by $0.79, MarketWatch Earnings reports. The business had revenue of $1.44 billion for the quarter, compared to analyst estimates of $1.27 billion. Alexion Pharmaceuticals had a net margin of 15.28% and a return on equity of 22.57%. Alexion Pharmaceuticals updated its FY 2020
Pre-Market guidance to 10.65-10.95 EPS.
NASDAQ:ALXN opened at $102.49 on Friday. The company has a current ratio of 4.79, a quick ratio of 3.82 and a debt-to-equity ratio of 0.24. The company has a 50-day moving average of $110.49 and a 200-day moving average of $102.94. Alexion Pharmaceuticals has a twelve month low of $72.67 and a twelve month high of $125.52. The firm has a market cap of $22.63 billion, a price-to-earnings ratio of 27.40, a price-to-earnings-growth ratio of 0.81 and a beta of 1.46.
Several research firms have issued reports on ALXN. BMO Capital Markets dropped their target price on Alexion Pharmaceuticals from $147.00 to $142.00 and set an “outperform” rating on the stock in a research report on Thursday, May 7th. Nomura reaffirmed a “buy” rating and set a $133.00 price objective on shares of Alexion Pharmaceuticals in a report on Wednesday, May 6th. Credit Suisse Group raised their target price on Alexion Pharmaceuticals from $142.00 to $147.00 and gave the company an “outperform” rating in a report on Monday, June 1st. BidaskClub cut shares of Alexion Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Thursday, July 23rd. Finally, Cfra cut their price target on shares of Alexion Pharmaceuticals from $165.00 to $159.00 and set a “strong-buy” rating for the company in a report on Wednesday, May 6th. Three investment analysts have rated the stock with a sell rating, seven have assigned a hold rating, sixteen have given a buy rating and one has issued a strong buy rating to the stock. The stock has an average rating of “Buy” and an average price target of $143.17.
Alexion Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and Soliris (eculizumab), a monoclonal antibody for the treatment of PNH, atypical hemolytic uremic syndrome (aHUS), and generalized myasthenia gravis.
Recommended Story: How to calculate the intrinsic value of a stock
Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.